| Dr Richard S Kuk, MD | |
|
2410 Atherholt Rd, Lynchburg, VA 24501-2148 | |
| (434) 200-5252 | |
| (434) 200-2862 |
| Full Name | Dr Richard S Kuk |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 21 Years |
| Location | 2410 Atherholt Rd, Lynchburg, Virginia |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588681316 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD.200760 (Louisiana) | Secondary |
| 207RC0001X | Internal Medicine - Clinical Cardiac Electrophysiology | 0101239211 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Centra Health - Lynchburg Gen Hospital | Lynchburg, VA | Hospital |
| Centra Bedford Memorial Hospital | Bedford, VA | Hospital |
| Centra Southside Community Hospital, Inc | Farmville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centra Medical Group Llc | 4789606088 | 603 |
| Centra Health, Inc | 6002719713 | 21 |
News Archive
QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis. This report covers the use of disease-modifying agents for the treatment of multiple sclerosis, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use.
U.S. Ambassador to Namibia Wanda Nesbitt writes in the State Department's "DipNote" blog, "Here in Namibia, the United States, through the President's Emergency Plan for AIDS Relief (PEPFAR), is working closely with the people and Government of Namibia to prevent new HIV infections, provide lifesaving HIV treatment to those who need it, and help put an end to AIDS in the country."
Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.
› Verified 1 days ago
| Entity Name | Centra Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649228966 PECOS PAC ID: 4789606088 Enrollment ID: O20051230000147 |
News Archive
QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis. This report covers the use of disease-modifying agents for the treatment of multiple sclerosis, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use.
U.S. Ambassador to Namibia Wanda Nesbitt writes in the State Department's "DipNote" blog, "Here in Namibia, the United States, through the President's Emergency Plan for AIDS Relief (PEPFAR), is working closely with the people and Government of Namibia to prevent new HIV infections, provide lifesaving HIV treatment to those who need it, and help put an end to AIDS in the country."
Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.
› Verified 1 days ago
| Entity Name | Centra Health, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770693939 PECOS PAC ID: 6002719713 Enrollment ID: O20191218000107 |
News Archive
QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis. This report covers the use of disease-modifying agents for the treatment of multiple sclerosis, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use.
U.S. Ambassador to Namibia Wanda Nesbitt writes in the State Department's "DipNote" blog, "Here in Namibia, the United States, through the President's Emergency Plan for AIDS Relief (PEPFAR), is working closely with the people and Government of Namibia to prevent new HIV infections, provide lifesaving HIV treatment to those who need it, and help put an end to AIDS in the country."
Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard S Kuk, MD 2410 Atherholt Rd, Lynchburg, VA 24501-2148 Ph: (434) 200-5252 | Dr Richard S Kuk, MD 2410 Atherholt Rd, Lynchburg, VA 24501-2148 Ph: (434) 200-5252 |
News Archive
QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).
Hemispherx Biopharma, Inc., announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease, that summarizes the results of a three year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine.
BioTrends is pleased to announce the publication of a new syndicated report, TreatmentTrends: Multiple Sclerosis. This report covers the use of disease-modifying agents for the treatment of multiple sclerosis, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth and expected future use.
U.S. Ambassador to Namibia Wanda Nesbitt writes in the State Department's "DipNote" blog, "Here in Namibia, the United States, through the President's Emergency Plan for AIDS Relief (PEPFAR), is working closely with the people and Government of Namibia to prevent new HIV infections, provide lifesaving HIV treatment to those who need it, and help put an end to AIDS in the country."
Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.
› Verified 1 days ago
Varsha Reddy Pothula Venkata, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 103 Clifton St, Lynchburg, VA 24501 Phone: 434-455-7100 Fax: 434-947-5909 | |
Dr. James D Cure, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1901 Thomson Dr, Lynchburg, VA 24501 Phone: 434-947-3908 Fax: 434-947-5948 | |
Edward Vincent Bonyak, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 2410 Atherholt Rd, Lynchburg, VA 24501 Phone: 434-200-5252 Fax: 434-200-5252 | |
Sally- Ann Tracy Mcintosh, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2215 Landover Pl, Lynchburg, VA 24501 Phone: 434-947-3944 Fax: 866-617-8273 | |
Dr. John Newton Clore, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 125 Nationwide Dr, Internal Medicine, Lynchburg, VA 24502 Phone: 434-200-3908 | |
Dr. Evan D. Ownby, MD Internal Medicine Medicare: May Accept Medicare Assignments Practice Location: 2410 Atherholt Rd, Lynchburg, VA 24501 Phone: 434-200-2712 Fax: 434-200-2851 | |
Dr. Samuel Omotoye, M.D., FRCPC Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2410 Atherholt Rd, Lynchburg, VA 24501 Phone: 434-200-2712 Fax: 434-200-2851 |